elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
PD-L1
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
PD-L1
RIS
0.007
(Research Intensity Score)
Papers
1214
Top papers
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
2025 · 313 citations
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
2025 · 289 citations
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
2025 · 248 citations
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
2023 · 544 citations
Copper metabolism in cell death and autophagy
2023 · 654 citations
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
2024 · 349 citations
Small Cell Lung Cancer
2025 · 158 citations
Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy
2023 · 391 citations
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
2020 · 1701 citations
Newest papers
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
2025 · 313 citations
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
2025 · 289 citations
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
2025 · 248 citations
Small Cell Lung Cancer
2025 · 158 citations
NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
2025 · 58 citations
Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives
2025 · 64 citations
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
2025 · 45 citations
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
2025 · 52 citations
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)
2025 · 38 citations
Browse all papers →
PD-L1's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
PD-L1's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link